George2020 makes a good point, to which I'll add. Revenue last...

George2020 makes a good point, to which I'll add. Revenue last year was about $1.5 million. There are about 100 million shares on offer. That makes a share price (based on existing revenue for the past year) around $0.12. So you could argue that the shares are overpriced at $0.50.

The market has already priced in the expectation that OSX will grow a lot, which is why it's at over twice the price it listed at. But at the moment, there's no sign of any major growth that would justify a higher price. Lots of promise with all the distribution deals, research partnerships, expansion into new areas of bone grafting... but no exciting sales numbers. The trajectory is promising, but like I said, that's already been priced in.

Re. the comparison with Afterpay, that company only recently turned a small profit. Amazon and Tesla didn't make one for years. Look at the valuation of those companies and it's clear that profit (and even revenue) isn't everything, if the market believes there's scope for both in the future. But OSX is not in the same category of global "must use" companies such as those, and has to put a lot more runs on the board before it will be valued higher.

I bought too early based on the story and regret that I didn't wait for the inevitable slide after listing. I still think it's a very good company with a great story, management, fundamentals and outlook, and will hold for 2-3 years. But it's now in the bottom draw I don't expect any sudden movement up. I am disappointed that for a company that has been around for 20 years and selling its products for over ten, it hasn't secured more distribution deals, more support from doctors and thus more sales.